Hepatic resection for "bCLC Stage A" hepatocellular carcinoma. the prognostic role of alpha-fetoprotein

Roberto Santambrogio, Enrico Opocher, Mara Costa, Matteo Barabino, Massimo Zuin, Emanuela Bertolini, Francesca De Filippi, Savino Bruno

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Our aim was to assess the capability of Barcelona Clinic Liver Cancer (BCLC) staging system in allocating stage A patients to hepatic resection (HR) and the effect on survival. Methods: We enrolled 132 patients with hepatocellular carcinoma (HCC) amenable to HR. All patients underwent ultrasound (US)-guided anatomical resection (≤2 segments) and then postoperative results were evaluated. Results: Results showed 95% of patients were Child A, 49% in BCLC A1, 21% in A2, 6% in A3, and 24% in A4. No 30-day mortality occurred. Overall survival got worse from A1 to A4 (P = 0.0271), while no differences were found in Childs A patients with or without portal hypertension (P = 0.1674). Multivariate analysis (Cox model) shows that only AFP (

Original languageEnglish
Pages (from-to)426-434
Number of pages9
JournalAnnals of Surgical Oncology
Volume19
Issue number2
DOIs
Publication statusPublished - Feb 2012

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Hepatic resection for "bCLC Stage A" hepatocellular carcinoma. the prognostic role of alpha-fetoprotein'. Together they form a unique fingerprint.

Cite this